Expansion of production capacity for reagents and consumables using funds from the capital increase
First written in FY2016. 17 of 22 entries say "Advanced", first in FY2017. Latest entry: FY2026.
1 other company's latest entry also says "Restated".
- FY2026RestatedAnnual report
「Expansion of the production system to meet strong reagent orders and response to BCP requirements」
Expanding production capacity to accommodate increased reagent orders and responding to the business continuity plan remain key priorities. - 2026-09-03AdvancedGeneral Meetings of Shareholders
「Expansion of the production system to meet strong reagent orders and response to BCP requirements」
大館試薬センターの核酸抽出試薬出荷数が前期比153％となり、試薬受注に対応する生産体制の拡充と安定供給が課題として明示された。 - FY2025AdvancedAnnual report
「The execution of a five-year ODM product supply agreement with ELITechGroup is leading to concrete improvements in the profitability of equipment, reagents, consumables and maintenance-related products. It is also expected to significantly improve the utilization rate of the second plant at the Otakan Reagent Center. Improved product supply capacity and a lower manufacturing cost ratio should improve margins, establishing the foundation for securing profits.」
The second plant progressed from the operations and capital investment stage to a stage in which improvements in utilization, supply capacity, cost ratio and margins are expected against the backdrop of a medium- to long-term supply agreement with ELITechGroup. - FY2025-H1AdvancedAnnual report
「The execution of a five-year OEM product supply agreement with ELITechGroup, which accounts for just over 50% of group sales, is leading to concrete improvements in the profitability of equipment, reagents, consumables and maintenance-related products. It is also expected to significantly improve the utilization rate of the second plant at the Otakan Reagent Center. Improved product supply capacity and a lower manufacturing cost ratio should improve margins, establishing the foundation for securing profits.」
Against the backdrop of the five-year OEM supply agreement with ELITechGroup, the company described measures establishing a foundation for improving utilization and supply capacity at the second plant of the Otakan Reagent Center, reducing the manufacturing cost ratio and improving margins. - FY2024AdvancedAnnual report
「As a result, a significant increase in the utilization rate of the second plant at the Otakan Reagent Center, which was built using the subsidy under the Domestic Investment Promotion Program for Supply Chain Resilience, is expected. This should improve product supply capacity and reduce the manufacturing cost ratio, leading to improved margins and establishing the foundation for securing profits from the 40th fiscal year onward.」
For the second plant, the focus progressed from construction and the start of operations using the subsidy to the expected improvement in utilization, supply capacity and cost ratio against the backdrop of the supply agreement with ELITechGroup. - FY2024-Q3AdvancedAnnual report
「Following receipt at the end of February of the subsidy under the Domestic Investment Promotion Program for Supply Chain Resilience, ¥2,018 million of the syndicated loan entered into in 2021 was repaid in accordance with the original contract, among other factors, resulting in a ¥2,170 million decrease in fixed liabilities, including long-term borrowings.」
The subsidy related to the development of production facilities was received, and ¥2,018 million of the syndicated loan was repaid in accordance with the contract. The funding and repayment plan for capital investment progressed to the execution stage, with the receipt and repayment completed. - FY2024-Q2AdvancedAnnual report
「Of the borrowings that may breach financial covenants, the amount of the supply chain subsidy for the long-term borrowings has been finalized, with receipt scheduled for the end of February, and repayment is planned in accordance with the contract.」
For the supply chain subsidy related to the development of production facilities, the receipt amount was finalized, and the scheduled receipt at the end of February and allocation to long-term debt repayment became concrete. - FY2024-Q1Expected receipt of subsidy and planned allocation to long-term debt repaymentAnnual report
「In addition, receipt during the fiscal year ending June 2024 of a subsidy under the Domestic Investment Promotion Program for Supply Chain Resilience is expected, and the funds are scheduled to be allocated to the repayment of long-term borrowings.」
For the subsidy related to the development of production facilities, receipt during the fiscal year ending June 2024 and allocation to long-term debt repayment were indicated. - FY2023AchievedAnnual report
「July 2022: PSS Otakan Reagent Center, Second Plant begins operations」
The expansion of production capacity for reagents and consumables progressed from the planning and capital investment stage to implementation, marked by the start of operations at the second plant of the Otakan Reagent Center. - FY2022AdvancedAnnual report
「During the fiscal year, we made capital investments totaling ¥2,249 million. The principal investments were for establishing a mass-production system for genetic (nucleic-acid) extraction reagent cartridges centered on the second plant at the Otate Reagent Center.」
Capital investments totaling ¥2,249 million were made during the fiscal year to establish a mass-production system for reagent cartridges centered on the second plant at the Otate Reagent Center. - FY2022-Q2AdvancedAnnual report
「Cash flow from investing activities decreased by ¥976 million, due mainly to payments of ¥888 million for the acquisition of property, plant and equipment and ¥87 million for the acquisition of intangible assets, compared with a decrease of ¥740 million in the same period of the previous year.」
During the six-month period, payments of ¥888 million for the acquisition of property, plant and equipment and ¥87 million for the acquisition of intangible assets were incurred, advancing production- and equipment-related investment. - FY2021AdvancedAnnual report
「The significant capital investment plans as of the end of the fiscal year were as follows: construction of the second plant at the Otate Reagent Center.」
For the second plant at the Otate Reagent Center, the plan called for ¥1,493 million for the building and ¥414 million for equipment. Building work was scheduled to start in April 2021 and finish in March 2022, while equipment work was scheduled to start in March 2021 and finish in May 2022. Payments already made for the building had reached ¥604 million. - FY2021-Q3AdvancedAnnual report
「At a meeting of the Board of Directors held on 1 April 2021, a resolution was passed to construct a new second plant at the Otate Reagent Center in Otate, Akita Prefecture, as described below.」
The Board of Directors resolved to construct a second plant at the Otate Reagent Center. The project is intended to establish a supply chain for extraction reagents and consumables kits, with an acquisition cost of approximately ¥1,454 million, construction scheduled to start in April 2021 and completion scheduled for March 2022. - FY2021-Q2AdvancedAnnual report
「Cash flow from investing activities decreased by ¥740 million, due mainly to payments of ¥628 million for the acquisition of property, plant and equipment and ¥111 million for the acquisition of intangible assets, compared with a decrease of ¥60 million in the same period of the previous year.」
During the six-month period, payments of ¥628 million for the acquisition of property, plant and equipment and ¥111 million for the acquisition of intangible assets were incurred, reflecting progress in production- and equipment-related investment. - FY2020AdvancedAnnual report
「During the fiscal year, we made capital investments totaling ¥230 million. The principal investments were the acquisition of manufacturing equipment and the production of molds.」
To expand reagent and consumables production capacity, capital investments totaling ¥230 million were made, mainly for the acquisition of manufacturing equipment and mold production. Establishing the Otate No. 2 Plant and developing domestic production sites using subsidies were also identified as priority themes. - FY2020-Q3RestatedAnnual report
「On the cost side, R&D expenses increased to ¥363 million, up 21.5% year on year, partly due to short-term product application development costs. In addition, depreciation expenses increased as a result of capital investments to reduce the cost of mass-producing reagents, among other factors, bringing selling, general and administrative expenses to ¥1,182 million, up 11.0% year on year.」
The increase in depreciation resulting from capital investments aimed at reducing the cost of mass-producing reagents continued to be reflected in expenses. - FY2020-Q2AdvancedAnnual report
「On the cost side, R&D expenses increased to ¥232 million, up 9.4% year on year, partly due to short-term product application development costs. In addition, depreciation expenses increased as a result of capital investments to reduce the cost of mass-producing reagents, among other factors, bringing selling, general and administrative expenses to ¥784 million, up 9.7% year on year.」
The increase in depreciation resulting from capital investments aimed at reducing the cost of mass-producing reagents continued to be reflected in expenses. R&D expenses were ¥232 million and selling, general and administrative expenses were ¥784 million. - FY2020-Q1AdvancedAnnual report
「On the cost side, R&D expenses increased to ¥113 million, up 10.1% year on year, partly due to short-term product application development costs. In addition, depreciation expenses increased as a result of capital investments to reduce the cost of mass-producing reagents, among other factors, bringing selling, general and administrative expenses to ¥388 million, up 14.7% year on year.」
Capital investments aimed at reducing the cost of mass-producing reagents were made, and the resulting increase in depreciation was reflected in expenses for the quarter. - FY2019AdvancedAnnual report
「During the fiscal year, we made capital investments totaling ¥96 million. The principal investments were the acquisition of manufacturing equipment and the production of molds.」
Capital investments totaling ¥96 million were made, mainly for the acquisition of manufacturing equipment and mold production. Plans also remained in place for ¥400 million of automation equipment, ¥200 million of consumables molds, and ¥200 million of expansion work at the Otate Reagent Center. - FY2018AdvancedAnnual report
「Otate Reagent Center: automation equipment, ¥400 million, funded with capital-increase proceeds, work scheduled to start in September 2018 and finish in December 2022. Consumables molds, ¥200 million, funded with capital-increase proceeds, work scheduled to start in October 2018 and finish in December 2021. Expansion work, ¥200 million, funded with capital-increase proceeds, work scheduled to start in September 2018 and finish in June 2019.」
A specific ¥800 million investment plan for the Otate Reagent Center was presented, comprising automation equipment, consumables molds, and expansion work funded with capital-increase proceeds, together with the scheduled start and completion dates. - FY2017AdvancedAnnual report
「During the fiscal year, we made capital investments totaling ¥270 million. The principal investments were the acquisition of land, building facilities and manufacturing equipment, and the production of molds.」
Capital investments totaling ¥270 million were made during the fiscal year to expand reagent and consumables production capacity, mainly for the acquisition of manufacturing equipment and mold production. - FY2016First statedAnnual report
「Plastic consumables manufacturing: complete set of molds, ¥256 million; plastic consumables manufacturing: complete set of automation equipment, ¥201 million; Otate Reagent Center: expansion work, ¥350 million; complete set of automated reagent manufacturing equipment, ¥221 million; land, ¥20 million. Work started in July 2015 and was scheduled for completion in June 2017.」
The capital investment plan scheduled for completion in June 2017 included manufacturing equipment for plastic consumables and reagents and expansion of the production site.